MapLight Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $363.45M
- P/E (TTM)
- –
- Dividend yield
- –
About MapLight Therapeutics
Pharmaceutical Preparations, SIC 2834
MapLight Therapeutics is a clinical-stage biopharmaceutical company that develops circuit-specific therapies for debilitating central nervous system disorders. The company operates a discovery platform to identify neural circuits causally linked to diseases and target those circuits for therapeutic modulation. Its lead product candidate is ML-007C-MA, a fixed-dose combination combining a muscarinic agonist with a peripherally acting anticholinergic agent. Its development programs serve individuals suffering from psychiatric and neurological conditions, specifically patients with schizophrenia and Alzheimer's disease psychosis.
The organization's operations include multiple clinical studies evaluated in healthy participants and patients across Phase 1 and Phase 2 clinical trials. Geographically, the company is incorporated in Delaware and conducts its business within the United States. MapLight Therapeutics maintains its principal executive offices and headquarters in Redwood City, California.
Summary of the business section of MapLight Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MapLight Therapeutics, Inc.
- Headquarters
- Redwood City, CA
- Address
- 800 Chesapeake Drive 94063
- Phone
- (650) 839-4360
- Website
- maplightrx.com
- Employees
- 133, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- MPLT
- Exchange
- Nasdaq
- IPO date
- Oct 27, 2025
- Shares outstanding
- 46M, Aug 7, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1770069
- CUSIP
- 56565P103
- ISIN
- US56565P1030
- EIN
- 83-2163243
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher A. Kroeger | Chief Executive Officer, Director | 1,370,790 |
| Kristopher Hanson | General Counsel | 137,044 |
| Jonathan Gillis | CAO and Interim CFO | 152,482 |
| Erin Pennock Foff | Chief Medical Officer | 312,261 |
| James Woodruff Lillie | Chief Scientific Officer | 210,110 |
| Anatol Kreitzer | Chief Discovery Officer | 180,926 |
| Vishwas Setia | Chief Financial Officer | 356,256 |
| Troy Cox | Director | 23,484 |
| George Pavlov | Director | 28,932 |
| Martin Babler | Director | 7,864 |
| Maria C. Walker | Director | 62,703 |
| Timothy John Garnett | Director | 67,581 |
| Nanna Liebach Luneborg | Director | 3,932 |
| Robert C. Malenka | Director | 348,138 |
| James D. Trenkle | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 22, 2019 | Name change | Name changed from Alvarado Therapeutics, Inc. to MapLight Therapeutics, Inc. |